Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer.

The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology.

It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial.

The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial.

The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.